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dhoice of Prosthetic Heart Valves: 20-Year
esults of the Edinburgh Heart Valve Trial
recent edition of the Journal carried a robust debate between
avid S. Bach (1) and Shahbudin H. Rahimtoola (2) on the choice
f prosthetic heart valves for individual patients requiring valve
eplacement surgery. Bach’s (1) thesis was that prosthetic heart
alves have evolved over the years to provide superior hemody-
amics and durability compared to older valves, which had been
ncluded in randomized trials. Rahimtoola’s (2) commentary, “The
ext generation of prosthetic heart valves needs a proven track
ecord of patient outcomes at 15 to 20 years,” emphasized the
mportance of obtaining long-term data not available for the newer
rostheses, and he stressed how important long-term data are from
rospective randomized trials.
Bach (1) notes that in the Edinburgh Heart Valve Trial there
as a trend favoring improved survival in association with the
echanical Bjork-Shiley prosthesis. We have recently published
ata from the 20-year follow-up of patients randomized in this
rial. Interestingly, the trend toward improved survival at 12 years
iminished as patients were followed for 20 years. Bach (1) also
oted, “However, freedom from all valve-related complications for
issue and mechanical prostheses was indistinguishable at 12
ears.” In fact, when we followed our patients for survival without
major event (i.e., freedom from death, re-operation, major
emorrhage, embolism, or endocarditis) there was a significantly
etter survival in favor of the Bjork-Shiley prosthesis for those
ndergoing mitral valve replacement (3). This benefit became
pparent after 10 to 12 years of follow-up and as survival cures
ontinued to separate thereafter.
This difference in survival without a major event was almost
ntirely accounted for by the increased need for re-operation in
atients who had received a bioprosthesis with increasing years of
ollow-up. There was no significant difference in survival without
major event in the subgroup of patients who had undergone
ortic valve replacement. These results would not support Bach’s
1) statement, namely that “Bioprostheses were superior to me-
hanical valves prior to 12 years after surgery and were equivalent
hereafter.” The risk of anticoagulant hemorrhage is of course not
imited to those patients receiving a mechanical valve. We noted an
ncrease in the use of anticoagulants in patients who had been
andomized to receive a bioprosthesis during the course of the trial.
t five years, 15% of patients with a porcine aortic prosthesis and
6% of those with a porcine mitral prosthesis were receiving
arfarin; by 15 years this proportion had risen to 33% and 57%,
espectively. The increasing use of warfarin with the passage of
ime reflected concomitant conditions such as atrial fibrillation and
hamber dilation favoring the use of long-term anticoagulation.
These results emphasize the need for prolonged follow-up of
atients in randomized trials of prosthetic heart valves as it is only
ith such prolonged follow-up that important differences between
rostheses are seen to emerge. It is perhaps ironic that data from
he Edinburgh Trial and the U.S. Department of Veterans Affairs
rial have provoked such debate within the editorial pages of the
ournal of the American College of Cardiology. We had submitted the
anuscript of the 20-year follow-up to the Journal more than a
ear prior to Bach’s (1) viewpoint and Rahimtoola’s (2) commen-
ary and previous editorial. The Journal declined our manuscript; Ccceptance may have cast more light than heat on the subsequent
ebate.
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EPLY
am glad Dr. Bloomfield concurs with and re-emphasizes the
mportance of obtaining long-term (15 to 20 years) follow-up
ata in patients with prosthetic heart valves (PHVs). The 20-year
esults of the Edinburgh Heart Valve trial (1) (Edinburgh trial) are
eviewed in the Journal of the American College of Cardiology series
ntitled “The Year in Cardiology” (2). This trial showed that at 20
ears the incidence of re-operation in patients receiving the porcine
HV was very much higher than in patients receiving the
echanical PHV; after mitral valve replacement it was 77.6%
ersus 13.4%  p  0.0001 (1), and after aortic valve replacement
t was 56.2% versus 7.4%, p  0.0001. In the Veterans Affairs (3)
nd Edinburgh trials (1), major differences between the mechanical
nd bioprostheses that were statistically significant appeared after
bout 10 to 12 years of follow-up.
I agree that the Edinburgh and Veterans Affairs trials are very
mportant and provide useful data, but they should not be used as
he sole source on which to choose a PHV (3–5). In the Edinburgh
rial (1), at 20 years the survival with original prosthesis intact was
etter with mechanical valve, but the total mortality was not
ignificantly different between a mechanical and porcine PHV.
oncardiac causes accounted for 23% to 28% of the deaths; data
PHV vs. non-PHV) on the cardiac causes of death in those with
echanical and porcine PHVs are not provided. This information
ight help to understand why all-cause mortality was not signif-
cantly different. It is of interest that the 30-day mortality of
e-operation was 14.2% (18.3% before 1987 and 9.4% after 1987)
1).
Finally, the review (4) had not dealt with stentless PHVs in any
etail because long-term follow-up data was not available. The
ommentary (5) was able to show that Dr. Bach’s (6) unbridled
